Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis b in patients with decompensated cirrhosis from a third-party us payer perspective

Naoky Tsai, Lennox Jeffers, Lael Cragin, Sonja Sorensen, Wenqing Su, Lisa Rosenblatt, Hong Tang, Tony Hebden, Timothy Juday

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint Dive into the research topics of 'Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis b in patients with decompensated cirrhosis from a third-party us payer perspective'. Together they form a unique fingerprint.

Medicine & Life Sciences

Business & Economics